Attempted suicide under high dose dopaminergic therapy including apomorphine.
Impulse control disorder during continuous subcutaneous apomorphine treatment (CAI) was recently reported. We describe a 54-year-old patient with familial Parkinson's disease, who after initiation of CAI in addition to high dose levodopa and amantadine, developed impulse control disorder (major financial loss related to risky transactions and self-medication), psychosis and depression, which lead up to attempted suicide. To our knowledge, this is the first case of attempted suicide under apomorphine treatment.
Department of Neurology and Psychiatry, General Hospital of the city of Linz, Krankenhaussstr. 9, 4020, Linz, Austria. walter.struhal@akh.linz.at
Walter
W
Struhal
Michael
M
Guger
Stephanie
S
Hödl
Sok-Chu
SC
Ung
Michael
M
Bach
Gerhard
G
Ransmayr
D001058:Apomorphine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced* / Q000517:prevention & control*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy*; D013406:Suicide, Attempted / Q000517:prevention & control*
D018491:Dopamine Agonists; D001058:Apomorphine